Table 4 Analysis of efficacy of weekly irinotecan and capecitabine as first- or second line treatment
Variable | First-line treatment (n = 30) | Second-line treatment (n = 22) | ||
|---|---|---|---|---|
| Â | Number (%) | 95% CI | Number (%) | 95% CI |
Overall survival | ||||
Deaths | 16 (53.3) | Â | 12 (54.5) | Â |
Median OS (months) | 16.3 | 10.47–22.13 | 10.7 | 5.80–15.60 |
Progression-free survival | ||||
Progression events | 25 (83.3) | Â | 20 (90.9) | Â |
Median PFS (months) | 8.5 | 6.22–10.78 | 5.0 | 1.74–8.26 |
Response | 27 | Â | 21 | Â |
ORR | 10 (37.0) | Â | 3 (14.3) | Â |
PR | 10 (37.0) | Â | 3 (14.3) | Â |
SD | 11 (40.7) | Â | 13 (61.9) | Â |
PD | 6 (22.2) | Â | 5 (23.8) | Â |
Treatment cycles | ||||
Total | 378 | Â | 266 | Â |
Median number of cycles (range) | 12 (1–50) | 12 (1–33) | ||
Median treatment period (months) | 3.7 | Â | 3.7 | Â |